gms | German Medical Science

27. Wissenschaftlicher Kongress der Deutschen Hochdruckliga

Deutsche Liga zur Bekämpfung des hohen Blutdrucks – Deutsche Hypertonie Gesellschaft e. V.

26. bis 29.11.2003, Bonn

Lercanidipine: a new third generation calcium antagonist with very good tolerability

Meeting Abstract (Hypertonie 2003)

  • presenting/speaker A. Marx - Berlin-Chemie AG (Berlin, D)
  • A. Lichtenthal - Berlin-Chemie AG (Berlin, D)
  • C. Milbredt - Berlin-Chemie AG (Berlin, D)
  • R. Ott - Berlin-Chemie AG (Berlin, D)
  • B. Zegenhagen-Phiong - Berlin-Chemie AG (Berlin, D)
  • S. Tegeler - Berlin-Chemie AG (Berlin, D)
  • R. Agrawal - Berlin-Chemie AG (Berlin, D)

Hypertonie 2003. 27. Wissenschaftlicher Kongress der Deutschen Hochdruckliga. Bonn, 26.-29.11.2003. Düsseldorf, Köln: German Medical Science; 2004. Doc03hochP14

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/hoch2003/03hoch114.shtml

Veröffentlicht: 11. November 2004

© 2004 Marx et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective

Lercanidipine is a new calcium antagonist belonging to the dihydropyridine family. It has, in spite of a short plasma half-life, a long duration of action due to its lipophilicity. It is as a long-acting calcium antagonist with a good antihypertensive efficacy and tolerability in clinical use. To investigate the efficacy and tolerability of lercanidipine in daily clinical practice 6.637 patients were enrolled in a post marketing surveillance study.

Methods

Patients with mild to moderate essential hypertension in whom their physicians considered to prescribe a dihydropyridine were conferred to lercanidipine 10 mg once daily with a 6-week follow-up. 6.637 patients were included into this multicenter observational study (mean +/- SD age 60.1 +/- 12.3 years, 49.8% women and body mass index 27.8 +/- 4.2 kg/m2).

In 96.5% of the cases patients had an essential hypertension. 4564 patients (68.8%) were previously treated with antihypertensive drugs and 2143 patients (32.3%) with more than one medication.

During the 6-week follow-up the blood pressure, heart rate and tolerability regarding the most common site effects of dihydropyridine calcium-channel blockers were measured at baseline, after 3 weeks (approximately) and after 6 weeks.

Results

After 6 weeks the systolic blood pressure (BP) reduced from 166.3 +/- 15.8 to 140.6 +/- 11.4 mmHg, the diastolic from 95.3 +/- 9.3 mmHg to 83.2 +/- 6.7 mmHg.

The mean heart rate did not change (from 76.8 beats/min to 74.5 beats/min).

Over 93% of the patients had a systolic BP reduction of > 10 mmHg, over 71% of > 20 mmHg and over 40% of > 30 mmHg. Over 86% of the patients had a diastolic BP reduction of > 5 mmHg, over 70% of > 10 mmHg and over 44% of > 20 mmHg.

The overall incidence of adverse events was < 1%, of which the most frequent were flushing, headache, and leg oedema.

Conclusion

In this multicenter observational study lercanidipine has shown a significant reduction of systolic and diastolic blood pressure with a placebo-like tolerability.